While pharmaceutical supply chains have become increasingly complex, the supply of many essential health products relies on a limited number of producers from a handful of major manufacturing hubs. Over-consolidation of the pharmaceutical market makes supply chains vulnerable to disruptions and impedes access to essential medicines for millions of patients, especially in low- and-middle-income countries.
We work to strengthen regional and local manufacturing capacity of medicines, vaccines, personal protective equipment, medical devices, and other health products to provide more equitable access for patients and communities worldwide.
Manufacturing medicines locally during COVID-19
Learn how local pharmaceutical manufacturers around the world are building their capabilities to help ensure uninterrupted access to quality medicines.
- White paper: Last-mile manufacturing of vaccines, April 2021
- White paper: Advancing local pharmaceutical production, August 2019 (PDF)
- Report: Strengthening manufacturing capacity to improve access to quality-assured essential medicines, December 2017 (PDF)
- GSK Chlorhexidine Digluconate (7.1%) gel technology transfer report, May 2019 (PDF)